Advances in individualized therapies targeting specific genetic conditions offer the promise of new treatments for rare diseases, but with so few patients, it can […]
BIO supports and seeks refinements to FDA’s Plausible Mechanism Framework Read More »
May is Women’s Health Month and in observation, Bio.News sat down with Ragasudha Botta, MBBS, PhD, MMSc, Senior Scientific Director, Critical Path for Parkinson’s
Recent medical breakthroughs are enabling better diagnostics for prostate cancer and Alzheimer’s and improving real-time imaging of tumors during surgery. The researchers behind these
Bayh-Dole Coalition report highlights eight American Innovators Read More »
May is both Lupus Awareness Month and Women’s Health Month. And the timing is apropos as lupus affects female patients at a far higher
Lupus Awareness Month meets Women’s Health Month: Advancing care, research, and advocacy Read More »
Since its founding in 1920, the National Health Council (NHC) has brought diverse organizations together to forge consensus and drive patient-centered health policy in
Q&A with National Health Council: Driving patient-centred policy Read More »
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
The field of bleeding disorders has seen monumental transformation. For many patients, biotech innovation has turned what was once a fatal diagnosis with a
Biotech innovation makes inroads against bleeding disorders Read More »
Reauthorization of federal seed funding, a top priority for BIO’s work with Congress, passed the House with hefty bipartisan support on March 17 and
SBIR reauthorization, a top BIO priority, is passed by Congress Read More »
The Medicare drug price “negotiation” process has entered its third year, with some evolution but continued complexity for patients and patient organizations. This year,
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing Read More »
Most Favored Nation (MFN) type drug pricing proposals that were proposed by the Centers for Medicare & Medicaid Innovation (CMMI) in December 2025 would
BIO Coffee Chat: MFN proposals would harm innovation and access Read More »
